Stock Detail
CERUS CORPORATION
Drugs
CERS @ Yahoo Finance | CERS Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $2.90 | $2.94 | $0.06 | 2.11% | 0.00 | $2.84 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $2.83 | $2.81 | 348,098 | 139.49M | 342,759 | -12.08 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 3.01 | 2.95 | 2.88 | 2.82 | 2.75 |
Stock Profile
Cerus Corporation develops products for cancer, infectious disease, and blood safety. It develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens. The company is also developing the INTERCEPT Blood System, which is based on the company's Helinx technology for controlling biological replication. The INTERCEPT Blood System is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, other pathogens, and white blood cells. This system targets and inactivates blood-borne pathogens, such as HIV and hepatitis B and C, as well as harmful white blood cells, while leaving the therapeutic properties of the blood components intact. Cerus is also developing a proprietary vaccine platform to stimulate the immune system to target and attack cancer cells and infectious diseases. The company has collaboration agreements with Baxter Healthcare Corporation and BioOne Corporation for the joint development of the INTERCEPT Blood System for platelets and plasma; and with MedImmune, Inc. to co-develop a therapeutic vaccine designed to treat cancers of the breast, prostate, and colon, as well as metastatic melanomas. Cerus was incorporated in 1991 and is based in Concord, California.